Keywords: update, b-ms, goes, imclone, shareholders, slightly, higher

UPDATE: B-MS goes to ImClone shareholders with slightly higher bid, which Icahn rejects

Article | 29 September 2008

Print This

Turning to a hostile stance in its attempts to gain control of Erbitux (cetuximab) partner ImClone Systems, US drug major ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in